Shanghai Junshi Biosciences Co., Ltd.

SHSC:1877 Stock Report

Market Cap: HK$26.5b

Shanghai Junshi Biosciences Past Earnings Performance

Past criteria checks 0/6

Shanghai Junshi Biosciences's earnings have been declining at an average annual rate of -24.4%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 14.3% per year.

Key information

-24.4%

Earnings growth rate

-17.9%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate14.3%
Return on equity-31.3%
Net Margin-124.2%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shanghai Junshi Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSC:1877 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 241,628-2,0231,4141,686
31 Dec 231,503-2,2831,3991,937
30 Sep 231,222-2,2001,2672,019
30 Jun 231,177-2,4731,2932,271
31 Mar 231,079-2,5351,2432,401
31 Dec 221,453-2,3881,2852,384
30 Sep 222,525-1,9241,3552,282
30 Jun 222,856-1,6431,2592,184
31 Mar 223,039-1,4951,2842,129
31 Dec 214,025-7211,3772,069
30 Sep 213,302-9451,3881,991
30 Jun 213,134-1,0601,4712,016
31 Mar 213,038-1,0621,4102,011
31 Dec 201,595-1,6691,1271,778
30 Sep 201,259-1,4188711,543
30 Jun 201,041-1,0567071,286
31 Mar 20868-600609968
31 Dec 19775-747537946
30 Sep 19528-732429802
30 Jun 19310-735298689
31 Mar 1979-992203662
31 Dec 181-717146538
30 Sep 180-516104453
30 Jun 180-43994377
31 Mar 180-34779289
31 Dec 171-32174275
30 Sep 179-279104172
30 Jun 175-24622239
31 Mar 179-19115658
31 Dec 164-13142122
30 Sep 164-1091380
30 Jun 162-831100
31 Mar 162-71970
31 Dec 153-58840
30 Sep 155-43700
30 Jun 157-27570
31 Mar 156-26500
31 Dec 146-25440

Quality Earnings: 1877 is currently unprofitable.

Growing Profit Margin: 1877 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1877 is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.

Accelerating Growth: Unable to compare 1877's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1877 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).


Return on Equity

High ROE: 1877 has a negative Return on Equity (-31.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.